首页> 外文期刊>The Internet Journal of Pulmonary Medicine >A Long-Term Survival Of Small Cell Lung Cancer Developed Diffuse Large B-Cell Lymphoma
【24h】

A Long-Term Survival Of Small Cell Lung Cancer Developed Diffuse Large B-Cell Lymphoma

机译:小细胞肺癌发展为弥漫性大B细胞淋巴瘤的长期生存

获取原文
       

摘要

We are reporting a rare case of a patient with a long-term survival of a small cell lung cancer (SCLC) who later developed a diffuse large B-cell lymphoma in the left neck. The patient was a smoker, and at age 50, was diagnosed with limited-stage small cell lung cancer. He was treated with chemotherapy and concurrent radiation therapy, and received prophylactic cranial irradiation resulting in a complete remission. Now, eight years later, he has developed an 8 cm mass at the supraclavicular lymph node. Biopsy confirmed a diffuse large B-cell lymphoma. His bone marrow was not involved. With treatment of intense chemotherapy and involved field radiation of the left neck, he is now in complete remission. Long-term survivors of SCLC may develop a second cancer including high-grade lymphoma. Thus, closely following up patients with SCLC is essential. Introduction SCLC is the fifth most common cause of cancer death in the United States; each year, almost 40,000 new cases are diagnosed.1-3 At the diagnosis, approximately 30% of patients with SCLC will have tumor confined to the hemithorax of origin, the mediastinum, or the supraclavicular lymph nodes. These patients are designated as having limited-stage SCLC. Patients with tumors have spread beyond the supraclavicular areas are stated to have extensive-stage SCLC. The majority of these patients will die of the disease.1-3 With intensive chemotherapy and radiation therapy, long-term survivors with SCLC are increasing.1-4 However, developing a second cancer is increasing including mainly non-small cell lung cancer, but rarely is a lymphoma.
机译:我们报道了一例罕见的小细胞肺癌(SCLC)长期生存的患者,该患者后来在左颈部发展为弥漫性大B细胞淋巴瘤。该患者为吸烟者,在50岁时被诊断出患有有限期小细胞肺癌。他接受了化学疗法和同时放疗的治疗,并接受了预防性颅骨放疗,导致完全缓解。现在,八年后,他在锁骨上淋巴结肿大了8厘米。活检证实为弥漫性大B细胞淋巴瘤。他的骨髓没有受累。经过激烈的化学疗法和左颈野外放射治疗,他现在完全缓解了。 SCLC的长期幸存者可能会发展出第二种癌症,包括高度淋巴瘤。因此,密切跟踪SCLC患者至关重要。简介SCLC是美国第五大最常见的癌症死亡原因。每年,将诊断出近40,000例新病例。1-3在诊断时,约30%的SCLC患者的肿瘤局限于原发性半胸腔,纵隔或锁骨上淋巴结。这些患者被指定为SCLC受限期。肿瘤患者已扩散到锁骨上区域以外,据称患有广泛期SCLC。这些患者中的大多数会死于疾病。1-3随着密集的化学疗法和放射治疗,SCLC的长期幸存者正在增加。1-4然而,第二种癌症的发展正在增加,主要包括非小细胞肺癌,但很少是淋巴瘤。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号